AstraZeneca publishes interim vaccine data in Lancet, reveals 10 hospitalizations, 1 death in pivotal control arms

Kyle Blankenship

After reading out interim results in mid-November, AstraZeneca has been hot on the heels of Pfizer and Moderna in getting its adenovirus-based vaccine past regulators’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca publishes interim vaccine data in Lancet, reveals 10 hospitalizations, 1 death in pivotal control arms

Kyle Blankenship

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Biogen gets $250M in Royalty Pharma deal for Phase 3 lupus program

After passing on M&A offers, Abcuro raises $200M in bid to become commercial drugmaker

Exclusive: Longevity startup targets renegade proteins linked to diabetes and obesity

SpringWorks lands FDA approval for nerve tumor treatment

Biohaven lands priority review on second-chance application for neurodegenerative drug

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

As­traZeneca pub­lish­es in­ter­im vac­cine da­ta in Lancet, re­veals 10 hos­pi­tal­iza­tions, 1 death in piv­otal con­trol arms

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

AstraZeneca publishes interim vaccine data in Lancet, reveals 10 hospitalizations, 1 death in pivotal control arms